Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study BioPharma Dive Source link
Here’s Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September The Globe and Mail Source link
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher? MarketBeat Source link
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced BioSpace Source link